AMBS Amarantus Bioscience Holdings Inc (CE)

0.0001

0.00 (0.00%)

20 May 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Amarantus Bioscience Holdings Inc (CE)	USOTC:AMBS	OTCMarkets	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	0.0001						0.00	01:00:00

AMARANTUS BIOSCIENCE - BUILDING UP THERAPEUTICS ASSETS

28/07/2015 6:15am

InvestorsHub NewsWire

EDISON EQUITY RESEARCH: AMARANTUS BIOSCIENCE - BUILDING UP THERAPEUTICS ASSETS

Amarantus has acquired several pre-commercial therapeutic assets in recent years, and intends to create value by furthering their development before out-licensing or commercialising them. The firm recently acquired ESS-W, which can shorten the time needed to treat severe burns. Eltoprazine aims to reduce involuntary movements associated with long-term levodopa therapy in Parkinson’s disease. These candidates provide long-term potential, and drive our $76m rNPV.

Amarantus BioScience is a San Francisco-based life sciences firm developing therapeutics in multiple indications. Eltoprazine is in Phase IIb trials for Parkinson’s disease, levodopa-induced dyskinesia (PD-LID). The company’ Diagnostics subsidiary targets unmet need in neurology.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports